The type 2 diabetes drug metformin is finally shown to slow aging! Aging needs to be calle

Well SupportedMetformin serves as a valuable tool to demonstrate the principle of targeting aging, paving the way for future, more effective drugs and combination therapies.

Well SupportedThe TAME study aims to gain FDA approval for aging as an indication.

Partially SupportedMetformin users had a 55% lower incidence of dementia in a large cohort study of diabetic patients.

Partially SupportedIn a high cardiovascular disease risk group, metformin reduced the incidence of CVD by 48.6%, cancer by 3.2%, depression by 2.8%, and frailty by 6.3%.

Partially Supported